Public Employees Retirement System of Ohio Sells 16,596 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Share on StockTwits

Public Employees Retirement System of Ohio decreased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 46.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,461 shares of the biotechnology company’s stock after selling 16,596 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in United Therapeutics were worth $1,519,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Renaissance Technologies LLC lifted its position in shares of United Therapeutics by 35.7% in the 2nd quarter. Renaissance Technologies LLC now owns 3,040,978 shares of the biotechnology company’s stock worth $237,379,000 after acquiring an additional 799,200 shares during the period. Quantamental Technologies LLC bought a new stake in shares of United Therapeutics in the 2nd quarter worth approximately $312,000. Pearl River Capital LLC bought a new stake in shares of United Therapeutics in the 2nd quarter worth approximately $32,000. Permanens Capital L.P. lifted its position in shares of United Therapeutics by 2.5% in the 2nd quarter. Permanens Capital L.P. now owns 6,150 shares of the biotechnology company’s stock worth $480,000 after acquiring an additional 150 shares during the period. Finally, Cutler Group LP bought a new stake in shares of United Therapeutics in the 2nd quarter worth approximately $288,000. Hedge funds and other institutional investors own 94.11% of the company’s stock.

In other United Therapeutics news, Director Raymond Dwek sold 3,750 shares of the business’s stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $76.11, for a total transaction of $285,412.50. Following the transaction, the director now owns 3,750 shares of the company’s stock, valued at $285,412.50. The sale was disclosed in a document filed with the SEC, which is available through this link. 8.80% of the stock is owned by insiders.

A number of brokerages have recently issued reports on UTHR. ValuEngine raised United Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. BidaskClub raised United Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. LADENBURG THALM/SH SH raised United Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $103.00 to $106.00 in a report on Thursday, August 1st. Zacks Investment Research cut United Therapeutics from a “buy” rating to a “hold” rating and set a $86.00 target price for the company. in a report on Wednesday, August 14th. Finally, Jefferies Financial Group raised United Therapeutics from an “underperform” rating to a “hold” rating and set a $90.00 price target for the company in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $121.73.

Shares of NASDAQ:UTHR traded up $2.98 during midday trading on Thursday, reaching $87.19. The company had a trading volume of 122,376 shares, compared to its average volume of 401,451. The company has a quick ratio of 4.41, a current ratio of 4.62 and a debt-to-equity ratio of 0.31. The business’s 50 day moving average price is $81.34 and its 200 day moving average price is $91.86. The stock has a market cap of $3.66 billion, a PE ratio of 6.51 and a beta of 0.92. United Therapeutics Co. has a 1-year low of $74.31 and a 1-year high of $129.59.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $4.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.40 by $2.26. The business had revenue of $373.60 million for the quarter, compared to the consensus estimate of $331.78 million. United Therapeutics had a negative return on equity of 4.54% and a negative net margin of 7.69%. On average, research analysts expect that United Therapeutics Co. will post -1.96 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Further Reading: What are the benefits of buying treasury bonds?

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.